Business Context and Reporting Period
Company: BridgeBio Pharma, Inc. (BBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: October 5, 2020
Event: Entry into a Material Definitive Agreement to acquire Eidos Therapeutics, Inc. (Eidos).
Key Financial Metrics and Transaction Terms
This filing details a merger agreement rather than periodic financial performance. Key transaction metrics include:
- Consideration per Eidos Share: Eidos stockholders may elect to receive either 1.85 shares of BridgeBio common stock or $73.26 in cash.
- Cash Cap: The aggregate cash consideration is capped at $175 million, subject to proration if elections exceed this limit.
- Termination Fees: Eidos must pay BridgeBio $35 million under certain termination scenarios; BridgeBio must pay Eidos $100 million under other scenarios.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either company.
Material Changes and Transaction Structure
The primary material change is the proposed acquisition of Eidos by BridgeBio via a two-step merger:
- Initial Merger: A BridgeBio subsidiary (Merger Sub) merges with and into Eidos, with Eidos surviving.
- Subsequent Merger: Eidos merges with and into a second BridgeBio subsidiary (Merger Sub II), with Merger Sub II surviving as an indirect wholly-owned subsidiary of BridgeBio.
Upon completion, Eidos common stock will cease to be listed on Nasdaq and will be deregistered under the Exchange Act.
Guidance, Outlook, Risks, and Contingencies
Conditions to Closing: The transaction is subject to several conditions, including:
- Approval by a majority of Eidos stockholders (excluding BridgeBio affiliates).
- Approval by at least 66-2/3% of Eidos voting shares not owned by BridgeBio or affiliates.
- Approval by a majority of BridgeBio stockholders voting on the issuance of new shares.
- SEC declaration of effectiveness for the Form S-4 registration statement.
- Listing approval of BridgeBio shares on Nasdaq.
Voting Support: Eidos has secured voting agreements with BridgeBio stockholders and board members owning approximately 36% of outstanding BridgeBio common stock to vote in favor of the share issuance.
Risks and Contingencies:
- Termination: The agreement may be terminated if not consummated by June 4, 2021, or if either board changes its recommendation.
- Operational Risks: Potential disruptions to business, inability to retain key personnel, and unexpected costs.
- Regulatory and Clinical Risks: Uncertainty regarding clinical development timelines, regulatory submissions, and the impact of the COVID-19 pandemic.
- Forward-Looking Statements: Actual results may differ materially from expectations regarding synergies and value creation.
Investor Verification Checklist
- Verify the final election ratio between cash and stock consideration from Eidos stockholders to determine the actual cash outlay (capped at $175 million).
- Monitor the status of the Form S-4 registration statement and the upcoming stockholder votes for both companies.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific covenants and termination rights.
- Assess the impact of the $100 million reverse termination fee on BridgeBio's liquidity if the deal fails due to Eidos board action.
- Confirm the timeline for the deregistration of Eidos stock and the integration of Eidos' assets into BridgeBio.